JB Chemicals Amalgamation Petition on June 11, 2026
May 11, 2026
Torrent Pharmaceuticals Limited has disclosed, under Regulation 30 of SEBI's LODR Regulations, 2015, that a Company Petition for the Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited was presented on 29th April 2026 and admitted by the NCLT, Ahmedabad Bench on 7th May 2026. The petition has been fixed for hearing before the Hon'ble Tribunal on Thursday, 11th June 2026. The disclosure was accompanied by newspaper advertisements published on 11th May 2026 across multiple editions in English and Gujarati. Interested parties may submit representations to the Tribunal and the respective company secretaries of both petitioner companies at least two days prior to the hearing date.
Torrent Pharmaceuticals Limited has filed a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing the stock exchanges of a Notice of Hearing of Petition in connection with the proposed Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited and their respective shareholders. The disclosure was made on 11th May 2026 and was accompanied by newspaper advertisement cuttings published in Indian Express (English) — all India Editions and Sandesh, Divya Bhaskar & Gujarat Samachar (Gujarati) — all in Gujarat Editions on 11th May 2026.
Amalgamation Petition Before NCLT
A Company Petition under Sections 230 and 232 and other applicable provisions of the Companies Act, 2013 has been filed for sanctioning the Scheme of Arrangement in the nature of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited (Petitioner Transferor Company / JB Pharma) with Torrent Pharmaceuticals Limited (Petitioner Transferee Company / Torrent Pharma) and their respective shareholders. The key procedural milestones in the petition process are outlined below:
Parameter: Details Petition Presented By: Petitioner Companies (Torrent Pharmaceuticals Limited & J.B. Chemicals & Pharmaceuticals Limited) Date of Presentation: 29th April 2026 Date of Admission: 7th May 2026 Admitting Authority: National Company Law Tribunal, Ahmedabad Bench Date Fixed for Hearing: Thursday, 11th June 2026 Legal Provisions Invoked: Sections 230 and 232 of the Companies Act, 2013
Details of the Petitioner Companies
The two companies involved in the proposed amalgamation are both incorporated under the Companies Act, 1956 and are registered in the State of Gujarat. Their details are as follows:
Parameter: J.B. Chemicals & Pharmaceuticals Limited Torrent Pharmaceuticals Limited Role: Petitioner Transferor Company (JB Pharma) Petitioner Transferee Company (Torrent Pharma) CIN: L24390GJ1976PLC173077 L24230GJ1972PLC002126 Registered Office: 302, Iscon Mall, Star India Bazar Building, Opp. Jodhpur BRTS, Satellite, Ahmedabad – 380015 Avirat, Thaltej Shilaj Road, Ahmedabad – 380059
Participation and Representation Process
Any person seeking to support or oppose the Company Petition at the hearing is required to submit an affidavit with the grounds of support or opposition in the form of a representation before the Hon'ble Tribunal. Such persons must also provide a written copy to the Petitioner Companies' Advocate, Swati Soparkar, at 301, Shivalik-10, Opp. SBI Zonal Office, Near Old Excise Chowky, S.M. Road, Ambavadi, Ahmedabad – 380 015, and/or at swati.soparkar@gmail.com .
Copies must also be addressed to the respective Company Secretaries and Compliance Officers of both petitioner companies:
JB Pharma: Mr. Sandeep Phadnis, Company Secretary & Compliance Officer, Neelam Centre, 'B' Wing, 4th floor, Hind Cycle Road, Worli, Mumbai 400030
Torrent Pharma: Mr. Chintan Trivedi, Company Secretary & Compliance Officer, Avirat, Thaltej Shilaj Road, Ahmedabad – 380 059, Gujarat, India
All representations must be received no later than two days before the date fixed for the hearing of the Company Petition. Interested parties may appear in person or through their advocate. A copy of the Company Petition will be furnished to any person requiring the same on payment of the prescribed charges.
Regulatory Disclosure
The disclosure was signed by Chintan M. Trivedi, Company Secretary of Torrent Pharmaceuticals Limited, and submitted to both BSE Limited and the National Stock Exchange of India Ltd. on 11th May 2026, in compliance with applicable SEBI listing regulations.
Torrent Pharmaceuticals has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Friday, May 22, 2026, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 9, 2026, and signed by Company Secretary Chintan M Trivedi.
Key Agenda Items for the Board Meeting
The Board meeting has been convened to address several significant matters. The following table outlines the key agenda items scheduled for deliberation:
Agenda Item: Details Financial Results: Audited Financial Results for the year ended March 31, 2026 Dividend Consideration: Recommendation of final dividend, if any, on equity shares for the year 2025-26 Fund Raising: Enabling resolutions for raising funds via QIP, Convertible Bonds/Debentures, Depository Receipts, or other modes Shareholder Approval: Fund-raising resolution, if approved by Board, to be placed before shareholders at the ensuing AGM
Audited Financial Results for FY26
The primary agenda of the May 22, 2026 Board meeting is the consideration and approval of the audited financial results of the company for the year ended March 31, 2026. This is a mandatory disclosure requirement under applicable SEBI regulations, and the results, once approved, will be disseminated to the stock exchanges.
Dividend and Fund-Raising Plans
Alongside the financial results, the Board will consider the recommendation of a final dividend, if any, on the equity shares of the company for the year 2025-26. The Board will also take up enabling resolutions for raising funds through the following instruments:
Issue of Equity Shares including Convertible Bonds/Debentures through Qualified Institutional Placement (QIP)
Depository Receipts
Any other permissible modes
If the Board approves the fund-raising resolution, the matter will subsequently be placed for shareholders' approval at the ensuing Annual General Meeting (AGM).
Regulatory Compliance
The intimation has been filed in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates prior notice to stock exchanges before Board meetings where financial results or dividend recommendations are to be considered. The notice was addressed to both BSE Limited and the National Stock Exchange of India Ltd.
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.
Disclaimer:
The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.
Amalgamation Petition Before NCLT
A Company Petition under Sections 230 and 232 and other applicable provisions of the Companies Act, 2013 has been filed for sanctioning the Scheme of Arrangement in the nature of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited (Petitioner Transferor Company / JB Pharma) with Torrent Pharmaceuticals Limited (Petitioner Transferee Company / Torrent Pharma) and their respective shareholders. The key procedural milestones in the petition process are outlined below:
Parameter: Details Petition Presented By: Petitioner Companies (Torrent Pharmaceuticals Limited & J.B. Chemicals & Pharmaceuticals Limited) Date of Presentation: 29th April 2026 Date of Admission: 7th May 2026 Admitting Authority: National Company Law Tribunal, Ahmedabad Bench Date Fixed for Hearing: Thursday, 11th June 2026 Legal Provisions Invoked: Sections 230 and 232 of the Companies Act, 2013
Details of the Petitioner Companies
The two companies involved in the proposed amalgamation are both incorporated under the Companies Act, 1956 and are registered in the State of Gujarat. Their details are as follows:
Parameter: J.B. Chemicals & Pharmaceuticals Limited Torrent Pharmaceuticals Limited Role: Petitioner Transferor Company (JB Pharma) Petitioner Transferee Company (Torrent Pharma) CIN: L24390GJ1976PLC173077 L24230GJ1972PLC002126 Registered Office: 302, Iscon Mall, Star India Bazar Building, Opp. Jodhpur BRTS, Satellite, Ahmedabad – 380015 Avirat, Thaltej Shilaj Road, Ahmedabad – 380059
Participation and Representation Process
Any person seeking to support or oppose the Company Petition at the hearing is required to submit an affidavit with the grounds of support or opposition in the form of a representation before the Hon'ble Tribunal. Such persons must also provide a written copy to the Petitioner Companies' Advocate, Swati Soparkar, at 301, Shivalik-10, Opp. SBI Zonal Office, Near Old Excise Chowky, S.M. Road, Ambavadi, Ahmedabad – 380 015, and/or at swati.soparkar@gmail.com .
Copies must also be addressed to the respective Company Secretaries and Compliance Officers of both petitioner companies:
JB Pharma: Mr. Sandeep Phadnis, Company Secretary & Compliance Officer, Neelam Centre, 'B' Wing, 4th floor, Hind Cycle Road, Worli, Mumbai 400030
Torrent Pharma: Mr. Chintan Trivedi, Company Secretary & Compliance Officer, Avirat, Thaltej Shilaj Road, Ahmedabad – 380 059, Gujarat, India
All representations must be received no later than two days before the date fixed for the hearing of the Company Petition. Interested parties may appear in person or through their advocate. A copy of the Company Petition will be furnished to any person requiring the same on payment of the prescribed charges.
Regulatory Disclosure
The disclosure was signed by Chintan M. Trivedi, Company Secretary of Torrent Pharmaceuticals Limited, and submitted to both BSE Limited and the National Stock Exchange of India Ltd. on 11th May 2026, in compliance with applicable SEBI listing regulations.
Torrent Pharmaceuticals has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Friday, May 22, 2026, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 9, 2026, and signed by Company Secretary Chintan M Trivedi.
Key Agenda Items for the Board Meeting
The Board meeting has been convened to address several significant matters. The following table outlines the key agenda items scheduled for deliberation:
Agenda Item: Details Financial Results: Audited Financial Results for the year ended March 31, 2026 Dividend Consideration: Recommendation of final dividend, if any, on equity shares for the year 2025-26 Fund Raising: Enabling resolutions for raising funds via QIP, Convertible Bonds/Debentures, Depository Receipts, or other modes Shareholder Approval: Fund-raising resolution, if approved by Board, to be placed before shareholders at the ensuing AGM
Audited Financial Results for FY26
The primary agenda of the May 22, 2026 Board meeting is the consideration and approval of the audited financial results of the company for the year ended March 31, 2026. This is a mandatory disclosure requirement under applicable SEBI regulations, and the results, once approved, will be disseminated to the stock exchanges.
Dividend and Fund-Raising Plans
Alongside the financial results, the Board will consider the recommendation of a final dividend, if any, on the equity shares of the company for the year 2025-26. The Board will also take up enabling resolutions for raising funds through the following instruments:
Issue of Equity Shares including Convertible Bonds/Debentures through Qualified Institutional Placement (QIP)
Depository Receipts
Any other permissible modes
If the Board approves the fund-raising resolution, the matter will subsequently be placed for shareholders' approval at the ensuing Annual General Meeting (AGM).
Regulatory Compliance
The intimation has been filed in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates prior notice to stock exchanges before Board meetings where financial results or dividend recommendations are to be considered. The notice was addressed to both BSE Limited and the National Stock Exchange of India Ltd.
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.
Disclaimer:
The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.